Dario J. Englot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dario J. Englot has a total of 675 co-authors. Here are the top co-authors by number of shared publications:
Edward F. Chang
30 shared publications- John D. Rolston
Department of Neurosurgery Mass General Brigham and Harvard Medical School Boston Massachusetts USA
28 shared publications - Victoria L. Morgan
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN
22 shared publications - Derek J. Doss
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN
11 shared publications Doris D. Wang
UCSF Comprehensive Epilepsy Center, University of California, San Francisco, California, USA
11 shared publications- Graham W. Johnson
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN
11 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Pediatric Epilepsy Surgery: Global Survey of Surgical Approaches
BACKGROUND AND OBJECTIVES: Pediatric epilepsy surgery is an established treatment, but current global data on surgical practices are limited. This study, conducted by the International League Against Epilepsy Pediatric Epilepsy Surgery Taskforce, provides an updated international overview of surgical approaches and their regional variation. METHODS: Group-level data were collected from 61 epilepsy surgery programs (49 pediatric-only) across 29 countries on 6 continents. All children and adolescents who underwent epilepsy surgery in 2023 were included. The study was designed to enable direct comparison with the similar survey conducted by the International League Against Epilepsy in 2004. RESULTS: The cohort comprised 2427 patients. Resections accounted for 50.6% and disconnections for 23.0% of procedures. Resection rates were highest in Oceania (87.3%) and lowest in North America (40.3%). Resections were 43.0% unilobar—most commonly temporal (39.6%) and frontal (32.7%)—and 9.7% multilobar, with 61.9% involving the posterior quadrant. Hemispheric surgeries comprised 12.9% of all cases (highest in South America: 18.1%). Subcortical procedures (eg, for hypothalamic hamartomas or deep-seated lesions) represented 2.7% (highest in South America: 12.1%). Intraoperative electrocorticography was used in 38.3% of cases, most commonly in Oceania (84.1%) and Asia (85.5%). Minimally invasive techniques were used in 7.7% of cases, with the highest rate in North America (16.9%). Laser interstitial thermal therapy was most common (4.9%), followed by radiofrequency ablation (2.1%), endoscopic surgery (0.7%), and radiosurgery (0.1%). Corpus callosotomy was performed in 5.9% of all cases, and no multiple subpial transections were reported. Neurostimulation was used in 14.7% of patients, highest in North America (35.6%), and included vagal nerve stimulation (11.8%), deep brain stimulation (1.5%), and responsive neurostimulation (1.4%). CONCLUSION: Resections and disconnections, including extensive multilobar and hemispheric procedures, remain the core procedures of pediatric epilepsy surgery. Although minimally invasive and neuromodulatory techniques are increasingly used in selected regions—particularly North America—their global adoption remains limited.
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Open AccessPediatric Epilepsy Surgery: Global Survey of Surgical Approaches
BACKGROUND AND OBJECTIVES: Pediatric epilepsy surgery is an established treatment, but current global data on surgical practices are limited. This study, conducted by the International League Against Epilepsy Pediatric Epilepsy Surgery Taskforce, provides an updated international overview of surgical approaches and their regional variation. METHODS: Group-level data were collected from 61 epilepsy surgery programs (49 pediatric-only) across 29 countries on 6 continents. All children and adolescents who underwent epilepsy surgery in 2023 were included. The study was designed to enable direct comparison with the similar survey conducted by the International League Against Epilepsy in 2004. RESULTS: The cohort comprised 2427 patients. Resections accounted for 50.6% and disconnections for 23.0% of procedures. Resection rates were highest in Oceania (87.3%) and lowest in North America (40.3%). Resections were 43.0% unilobar—most commonly temporal (39.6%) and frontal (32.7%)—and 9.7% multilobar, with 61.9% involving the posterior quadrant. Hemispheric surgeries comprised 12.9% of all cases (highest in South America: 18.1%). Subcortical procedures (eg, for hypothalamic hamartomas or deep-seated lesions) represented 2.7% (highest in South America: 12.1%). Intraoperative electrocorticography was used in 38.3% of cases, most commonly in Oceania (84.1%) and Asia (85.5%). Minimally invasive techniques were used in 7.7% of cases, with the highest rate in North America (16.9%). Laser interstitial thermal therapy was most common (4.9%), followed by radiofrequency ablation (2.1%), endoscopic surgery (0.7%), and radiosurgery (0.1%). Corpus callosotomy was performed in 5.9% of all cases, and no multiple subpial transections were reported. Neurostimulation was used in 14.7% of patients, highest in North America (35.6%), and included vagal nerve stimulation (11.8%), deep brain stimulation (1.5%), and responsive neurostimulation (1.4%). CONCLUSION: Resections and disconnections, including extensive multilobar and hemispheric procedures, remain the core procedures of pediatric epilepsy surgery. Although minimally invasive and neuromodulatory techniques are increasingly used in selected regions—particularly North America—their global adoption remains limited.
- Open Access
- 27 October 2026
- Published by MIT Press in Imaging Neuroscience
- Vol. 4
Longitudinal quantitative streamline tractography: Robust estimation of white matter connectivity differences
Longitudinal probing of structural connectivity via diffusion magnetic resonance imaging (dMRI) is experiencing uptake. However, the detection of biological effects is significantly hampered by the limitations of cross-sectional streamline tractography, where even small changes in the dMRI signal can produce drastically different trajectories and, therefore, quantitative parameterisation; if not properly dealt with, such effects will manifest as spurious longitudinal change, which can obscure subtle biological differences. To address this challenge, we here introduce a novel quantitative streamline tractography framework tailored for longitudinal analysis, wherein an individual’s streamline trajectories remain fixed throughout the analysis, allowing only their ascribed density weights to vary between sessions. We present two strategies by which these quantitative streamline weights can be determined, both extensions of the widely adopted SIFT2 method. The performance of this framework is benchmarked against cross-sectional reconstruction with and without SIFT2 optimisation, in both in silico dMRI phantoms with known ground truths and three distinct human in vivo cohorts with clear a priori expectations of biological effects. We demonstrate that the proposed framework drastically reduces methodological imprecisions in synthetic dMRI phantoms and enhances statistical sensitivity and specificity to biological effects in human cohorts, enabling more robust quantification of longitudinal structural connectivity differences.
- 27 October 2026
- Published by MIT Press in Imaging Neuroscience
- Vol. 4
Open AccessLongitudinal quantitative streamline tractography: Robust estimation of white matter connectivity differences
Longitudinal probing of structural connectivity via diffusion magnetic resonance imaging (dMRI) is experiencing uptake. However, the detection of biological effects is significantly hampered by the limitations of cross-sectional streamline tractography, where even small changes in the dMRI signal can produce drastically different trajectories and, therefore, quantitative parameterisation; if not properly dealt with, such effects will manifest as spurious longitudinal change, which can obscure subtle biological differences. To address this challenge, we here introduce a novel quantitative streamline tractography framework tailored for longitudinal analysis, wherein an individual’s streamline trajectories remain fixed throughout the analysis, allowing only their ascribed density weights to vary between sessions. We present two strategies by which these quantitative streamline weights can be determined, both extensions of the widely adopted SIFT2 method. The performance of this framework is benchmarked against cross-sectional reconstruction with and without SIFT2 optimisation, in both in silico dMRI phantoms with known ground truths and three distinct human in vivo cohorts with clear a priori expectations of biological effects. We demonstrate that the proposed framework drastically reduces methodological imprecisions in synthetic dMRI phantoms and enhances statistical sensitivity and specificity to biological effects in human cohorts, enabling more robust quantification of longitudinal structural connectivity differences.
- Open Access
- 11 October 2026
- Published by Elsevier in SSRN Electronic Journal
Identity-Duplication Auditing in National-Scale Neuroimaging Repositories
Objective . National-scale magnetic resonance imaging (MRI) repositories increasingly integrate data from different studies and institutions. However, subject identifiers that are valid only within individual datasets are no longer guaranteed to remain globally unique after aggregation, making it possible for the same subject to be assigned multiple identifiers, which we define as identity duplication. Such duplication can create leakage between training and test data and inflate apparent performance in downstream biomedical studies. Existing methods do not provide an end-to-end, image-based workflow for auditing this problem at repository scale. Methods. HAPPEN is a human-in-the-loop pipeline for auditing identity duplication in T1-weighted brain MRI repositories. It combines SHA-256 fingerprinting for exact-duplicate detection with supervised contrastive retrieval of non-identical scans that may originate from the same person. Retrieved pairs are reviewed as candidates in a locally hosted interface rather than automatically classified as duplicates. We benchmarked retrieval against PCA and 3D-SIFT-Rank in an internal test set and two withheld cohorts. We deployed the workflow in a 95,129-scan aggregated repository and assessed end-to-end recovery using 54 genetic-reference pairs. Transferability was assessed by locally deploying the same workflow on 22,386 scans at an independent institution without model retraining or image transfer.Results. HAPPEN achieved near-ceiling same-subject retrieval across all three cohorts and matched or exceeded the baseline point estimates on every metric. Deployment in the study repository identified 1,316 exact-duplicate scan groups and 1,275 reviewer-supported near-duplicate subject groups. Of these groups, 56% and 82%, respectively, crossed dataset boundaries. All 54 genetic-reference pairs were recovered. The external team independently completed the full workflow using a locally selected operating threshold and review standard.Conclusion. Together, these findings indicate that identity duplication is a structural risk of MRI repository aggregation and that HAPPEN can support practical, locally governed quality assurance.
- 11 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIdentity-Duplication Auditing in National-Scale Neuroimaging Repositories
Objective . National-scale magnetic resonance imaging (MRI) repositories increasingly integrate data from different studies and institutions. However, subject identifiers that are valid only within individual datasets are no longer guaranteed to remain globally unique after aggregation, making it possible for the same subject to be assigned multiple identifiers, which we define as identity duplication. Such duplication can create leakage between training and test data and inflate apparent performance in downstream biomedical studies. Existing methods do not provide an end-to-end, image-based workflow for auditing this problem at repository scale. Methods. HAPPEN is a human-in-the-loop pipeline for auditing identity duplication in T1-weighted brain MRI repositories. It combines SHA-256 fingerprinting for exact-duplicate detection with supervised contrastive retrieval of non-identical scans that may originate from the same person. Retrieved pairs are reviewed as candidates in a locally hosted interface rather than automatically classified as duplicates. We benchmarked retrieval against PCA and 3D-SIFT-Rank in an internal test set and two withheld cohorts. We deployed the workflow in a 95,129-scan aggregated repository and assessed end-to-end recovery using 54 genetic-reference pairs. Transferability was assessed by locally deploying the same workflow on 22,386 scans at an independent institution without model retraining or image transfer.Results. HAPPEN achieved near-ceiling same-subject retrieval across all three cohorts and matched or exceeded the baseline point estimates on every metric. Deployment in the study repository identified 1,316 exact-duplicate scan groups and 1,275 reviewer-supported near-duplicate subject groups. Of these groups, 56% and 82%, respectively, crossed dataset boundaries. All 54 genetic-reference pairs were recovered. The external team independently completed the full workflow using a locally selected operating threshold and review standard.Conclusion. Together, these findings indicate that identity duplication is a structural risk of MRI repository aggregation and that HAPPEN can support practical, locally governed quality assurance.
- 22 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (6)
Autonomic Network Signatures of Interictal Cardiorespiratory Dysfunction in Patients With Temporal Lobe Epilepsy
- 22 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (6)
Autonomic Network Signatures of Interictal Cardiorespiratory Dysfunction in Patients With Temporal Lobe Epilepsy
- Open Access
- 1 September 2026
- Published by SAGE Publications in Epilepsy Currents
Career Journeys in the American Epilepsy Society
- 1 September 2026
- Published by SAGE Publications in Epilepsy Currents
Open AccessCareer Journeys in the American Epilepsy Society
- Open Access
Perils and progress in epilepsy surgery utilization: Twenty‐five years later
More than 25 years have passed since the first randomized controlled trial (RCT) established that surgery is superior to continued anti‐seizure medication (ASM) for drug‐resistant temporal lobe epilepsy, and nearly as long since a joint practice parameter urged that appropriate surgical candidates be referred to a specialized center for evaluation—guidance that subsequent consensus has since broadened to all patients with drug‐resistant epilepsy. Despite Class I evidence and durable guidelines, epilepsy surgery remains one of the most underutilized effective interventions in medicine: fewer than 1% of potentially eligible patients are referred, and those who are referred reach a center on average two decades after seizure onset. This critical review, framed primarily around U.S. data and supplemented by a dedicated assessment of the global picture, examines the scope and burden of drug‐resistant epilepsy (DRE), the foundational evidence and guideline history, and the magnitude, patterns, and causes of persistent underutilization, including a distinct discussion of pediatric care and of disparities by race, insurance, and geography. We then turn to grounds for optimism. Surgical candidacy has materially expanded through minimally invasive approaches to both monitoring (stereo‐electroencephalography) and treatment (laser interstitial thermal therapy and neuromodulation), and indications have broadened to include selected generalized and multifocal epilepsies through thalamic neuromodulation. Contemporary International League Against Epilepsy (ILAE) recommendations go further still, extending referral even to selected patients who are seizure‐free on medication but harbor a surgically accessible lesion. We also raise a counterbalancing concern: the welcome diffusion of minimally invasive options should not eclipse resective and disconnective surgery, which remain the only potentially curative options validated by RCTs. We conclude that, 25 years on, underutilization persists as a major and partly remediable problem, and we offer recommendations for closing the surgical gap.
Open AccessPerils and progress in epilepsy surgery utilization: Twenty‐five years later
More than 25 years have passed since the first randomized controlled trial (RCT) established that surgery is superior to continued anti‐seizure medication (ASM) for drug‐resistant temporal lobe epilepsy, and nearly as long since a joint practice parameter urged that appropriate surgical candidates be referred to a specialized center for evaluation—guidance that subsequent consensus has since broadened to all patients with drug‐resistant epilepsy. Despite Class I evidence and durable guidelines, epilepsy surgery remains one of the most underutilized effective interventions in medicine: fewer than 1% of potentially eligible patients are referred, and those who are referred reach a center on average two decades after seizure onset. This critical review, framed primarily around U.S. data and supplemented by a dedicated assessment of the global picture, examines the scope and burden of drug‐resistant epilepsy (DRE), the foundational evidence and guideline history, and the magnitude, patterns, and causes of persistent underutilization, including a distinct discussion of pediatric care and of disparities by race, insurance, and geography. We then turn to grounds for optimism. Surgical candidacy has materially expanded through minimally invasive approaches to both monitoring (stereo‐electroencephalography) and treatment (laser interstitial thermal therapy and neuromodulation), and indications have broadened to include selected generalized and multifocal epilepsies through thalamic neuromodulation. Contemporary International League Against Epilepsy (ILAE) recommendations go further still, extending referral even to selected patients who are seizure‐free on medication but harbor a surgically accessible lesion. We also raise a counterbalancing concern: the welcome diffusion of minimally invasive options should not eclipse resective and disconnective surgery, which remain the only potentially curative options validated by RCTs. We conclude that, 25 years on, underutilization persists as a major and partly remediable problem, and we offer recommendations for closing the surgical gap.
- Open Access
Pediatric epilepsy surgery: Global survey of invasive explorations
Objective: Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods: Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results: A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance: This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.
Open AccessPediatric epilepsy surgery: Global survey of invasive explorations
Objective: Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods: Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results: A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance: This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.
- Open Access
Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Objective: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods: NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results: Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance: NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.
Open AccessResponsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Objective: This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods: NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results: Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance: NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.
- Open Access
Pediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices
Objective: Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods: Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results: Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were 5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.
Open AccessPediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices
Objective: Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods: Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results: Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were 5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.
- Open Access
- 2 June 2026
- Published by Springer Nature in Nature
- Vol. 654 (8119) , E20
Publisher Correction: White matter micro- and macrostructure brain charts for the human lifespan
- 2 June 2026
- Published by Springer Nature in Nature
- Vol. 654 (8119) , E20
Open AccessPublisher Correction: White matter micro- and macrostructure brain charts for the human lifespan